Interferon regulatory factor 5 (IRF5) and signal transducer and activator of transcription 4 (STAT4) are shared susceptibility genes for various autoimmune diseases. In this study, we investigated whether these genes also contribute to susceptibility to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a Japanese population. A case-control study was carried out on IRF5 rs10954213 and STAT4 rs7574865 in 232 Japanese myeloperoxidase (MPO)-ANCA-positive AAV patients, including 177 microscopic polyangiitis and 710 healthy controls. IRF5 rs10954213G was significantly increased in MPO-ANCA-positive AAV (additive model, P ¼ 0.023, odds ratio ¼ 1.27, 95% confidence interval ¼ 1.03-1.57). The risk allele was previously shown to be associated with lower mRNA level of IRF5. On the other hand, significant association of STAT4 rs7574865T with AAV was not detected. These observations suggested that IRF5 may contribute to susceptibility to MPO-ANCA-positive AAV in a Japanese population.
INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic GPA. MPA and eosinophilic GPA are mainly associated with myeloperoxidase (MPO)-ANCA, whereas GPA is associated with proteinase 3-ANCA. Geographic difference in the type of AAV is well known. GPA is the most common subtype in northern European populations, whereas MPA is predominant in the Japanese. 1 The positivity of ANCA is also different. MPA (91.8%) are positive for MPO ANCA in Japanese, 2 but it is 58% in Europeans. 3 Genetic differences between the subsets of AAV have been suggested, which was supported by a recent genome-wide association study in European populations. 4 Although proteinase 3-ANCA-positive AAV was associated with the HLA-DP region, SERPINA1 and PRTN3, MPO-ANCA-positive AAV was found to be associated with the HLA-DQ region.
AAV shares some genetic factors with various autoimmune diseases. PTPN22 R620W polymorphism is associated with several autoimmune diseases, such as type 1 diabetes, systemic lupus erythematosus (SLE) and GPA in European populations, [5] [6] [7] whereas the 620W allele is very rare in Asian populations. We previously reported an association of HLA-DRB1*09:01-DQB1*03:03 haplotype with MPA and MPO-ANCA-positive AAV in a Japanese population. 8, 9 This haplotype is one of the most common DRB1-DQB1 haplotypes in East Asian populations, but is very rare in Europeans. Association of HLA-DRB1*09:01 was also observed in various autoimmune diseases, including SLE and rheumatoid arthritis in the Japanese population. 10, 11 These observations also indicate the existence of population difference in the genetic background of AAV. Although the genome-wide association study includes the data of MPO-ANCApositive AAV in Europeans, 4 the genetics of MPA or MPO-ANCApositive AAV has not been well defined in the Asians.
Interferon (IFN) regulatory factor 5 (IRF5) and signal transducer and activator of transcription 4 (STAT4) genes were identified as susceptibility genes shared by multiple autoimmune diseases. [12] [13] [14] [15] IRF5 is involved in the production of type I IFN and proinflammatory cytokines. 12 Our previous observation indicated that IRF5 single-nucleotide polymorphism (SNP) rs10954213A, located in the 3'-untranslated region, which alters the polyA signal, conferred risk to systemic sclerosis in the Japanese. 13 STAT4 is a transcription factor essential for interleukin-12-mediated Th1 differentiation. 16 We reported the association of STAT4 rs7574865 with SLE and systemic sclerosis in the Japanese. 14, 15 In view of the epidemiological data suggesting the shared genetic background between AAV and other autoimmune diseases, 17 we thought that IRF5 and STAT4 might be good candidates for the susceptibility genes to AAV. In the present study, we examined genetic association of IRF5 and STAT4 polymorphisms with AAV in a Japanese population. As the genome-wide association study in the European populations clearly demonstrated that the auto-antibody profile is more strongly associated with genotypes than clinical classification, 4 and the majority of AAV patients were positive for MPO-ANCA in the Japanese population, 1 this study was limited to the patients positive for MPO-ANCA.
RESULTS AND DISCUSSION
To examine whether the IRF5 3'-untranslated region SNP rs10954213 is associated with AAV in the Japanese, a casecontrol study was carried out in 232 MPO-ANCA-positive AAV patients and 710 healthy controls. As shown in Table 1 , 177 patients were classified as MPA. The genotype frequencies are shown in Table 2 . The IRF5 rs10954213G allele was found to be increased in MPO-ANCA-positive AAV compared with that in healthy controls (additive model, P ¼ 0.023, odds ratio (OR) ¼ 1.27 per allele, 95% confidence interval (CI) ¼ 1.03-1.57). This association remained significant after correction for multiple testing (allele model, Q ¼ 0.023). Association of rs10954213G was also observed when the patients were limited to MPO-ANCA-positive MPA (additive model, P ¼ 0.023, OR ¼ 1.31, 95% CI ¼ 1.04-1.66).
The control group was substantially younger than the cases. However, the association remained significant when only the patients and controls older than 50 years were compared (P ¼ 5.5 Â 10
, OR ¼ 2.06, 95% CI ¼ 1.37-3.11). These findings suggested a possibility that IRF5 may contribute to the genetic predisposition to MPO-ANCA-positive AAV in the Japanese population. rs10954213 is located at the polyA signal, and the substitution of A-G results in the disruption of the polyA signal. In the mRNA transcribed from the G allele, an alternative polyA signal located downstream is employed, which alters the stability of IRF5 mRNA, thereby reducing the mRNA level of IRF5 (ref. 12) Thus, rs10954213G, the risk allele for MPO-ANCA-positive AAV, was considered to be associated with a lower expression of IRF5. This is in contrast with SLE 12 and systemic sclerosis, 13 where the opposite allele, rs10954213A, has been shown to be associated with the risk.
IRF5 facilitates the type I IFN pathway by inducing type I IFN and IFN-inducible genes. 12 Increased expression of type I IFN and IFNrelated genes has been reported in SLE and systemic sclerosis, 12, 18 which is considered to have a significant role in the pathogenesis of these diseases. On the other hand, the expression profiling of AAV has not reported IFN signature. 19, 20 Furthermore, Uno et al. 21 recently reported an impairment of IFNa production in Japanese patients with MPO-ANCA-positive AAV. Our data may suggest that a genetically determined low type I IFN response might have a function in the occurrence of MPO-ANCA-positive AAV. To our knowledge, type I IFN pathway genes have not been intensively examined for their association with MPO-ANCA-positive AAV, and are considered to be important candidates in future association studies.
Alternatively, our findings may imply that pathways other than the type I IFN pathway might account for the genetic risk associated with IRF5 polymorphism. IRF5 has been shown to regulate the expression of not only type I IFN-related genes but also a large number of genes involved in other pathways, such as apoptosis and cell cycle. 22 In contrast to the MPO-ANCA-positive AAV in the Japanese, IRF5 rs10954213G has been shown to be decreased in GPA in the European population. 23 This might be caused by the genetic differences between MPA and GPA, and/or the difference of genetic background between the populations. The current study included only 28 MPO-ANCA-positive patients with GPA, the result of which was not substantially different from MPA. However, to elucidate which possibility is true, association study with sufficient number of proteinase 3-ANCA-positive AAV or GPA in the Japanese population is necessary.
We previously reported an association of the intronic SNPs, rs6953165 and rs41298401, with SLE in the Japanese. 24 Significant association of these SNPs with MPO-ANCA-positive AAV was not observed (rs6953165: P ¼ 0.14, OR ¼ 1.34, 95% CI ¼ 0.91-1.98; rs41298401: P ¼ 0.25, OR ¼ 0.85, 95% CI ¼ 0.65-1.12).
We next conducted the association study of STAT4 rs7574865T, which is a shared susceptibility allele in various autoimmune diseases. rs7574865T/T genotype showed a tendency toward increase in MPO-ANCA-positive AAV (15.5%) when compared with healthy controls (11.1%, P ¼ 0.077, OR ¼ 1.47, 95% CI ¼ 0.96-2.25), although the difference did not reach statistical significance.
To our knowledge, there is no report that described an association of STAT4 with MPA. In the case of GPA, a metaanalysis did not show significant association of STAT4 rs7574865 in European populations. In conclusion, the association of IRF5 with MPO-ANCA-positive AAV was observed in a Japanese population. The risk allele of IRF5 was associated with lower expression of IRF5. These results should be confirmed in future studies.
PATIENTS AND METHODS

Patients and controls
Two hundred and thirty-two AAV patients positive for MPO-ANCA and 710 healthy controls, all unrelated Japanese, were studied. The patients were recruited from multiple rheumatology centers as a collaborative effort of the Intractable Vasculitis Syndromes Research Groups organized by the Ministry of Health, Labour and Welfare of Japan, as well as collaboration groups headed by the Sagamihara National Hospital and the Tokyo Medical and Dental University. Characteristics of the patients and controls are shown in Table 1 . The patients were classified according to the European Medicines Agency algorithm. 26 MPO-ANCA was measured by an enzyme-linked immunosorbent assay. This study was reviewed and approved by the Ethics Committee of each participating institute, and the subjects provided informed consent.
Genotyping
IRF5 rs10954213 and STAT4 rs7574865 were genotyped using 7300 RealTime PCR System (Applied Biosystems, Foster City, CA, USA) by a customdesigned TaqMan SNP Genotyping Assay and pre-designed TaqMan SNP Genotyping Assay (C__29882391_10), respectively.
Statistical analysis
Association was tested by logistic regression analysis or w 2 -test using 2 Â 2 contingency tables. To correct for multiple testing, the false discovery rate Q-value was calculated by SNPAlyze Ver.8.0.1 Pro (DYNACOM Co., Ltd, Chiba, Japan).
